CALIPHARMS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | 0.00% |
| 2018 | CaliPharms, Inc. Launches a New CBD Muscle & Joint Relief Roll On Gel | CI |
| 2018 | Joe Pavlik Joins the Advisory Board of CaliPharms, Inc | CI |
| Sales 2012 | - | Sales 2013 | - | Capitalization | 8.23M 686M |
|---|---|---|---|---|---|
| Net income 2012 | - 0 | Net income 2013 | - 0 | EV / Sales 2012 * | - |
| Net Debt 2012 | 617K 51.42M | Net Debt 2013 | 667K 55.59M | EV / Sales 2013 | - |
| P/E ratio 2012 * |
-
| P/E ratio 2013 |
-0.51
x | Employees | - |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
Current year
0.00
0.00
1 year
0.000.00
3 years
0.000.00
5 years
0.000.00
10 years
0.000.01
CaliPharms Inc is a developmental stage acquisition company. The Company is focused on acquiring, merging, and joint venturing with legally permitted fully operational marijuana-cannabis businesses. The Company is seeking acquisitions in medical marijuana-cannabis cultivation. The Company focuses on the medical-grade marijuana-cannabis within the State of California. The Company is also expanding into other sectors that support the legalized marijuana industry.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 13.88K | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- KGET Stock
